WaveWriter Alpha 16 implantable pulse generator.

WaveWriter Alpha™ Spinal Cord Stimulator System

The WaveWriter Alpha SCS System provides our broadest range of offerings that can be customized to treat your patients’ unique pain. With rechargeable and recharge-free 16-contact and 32-contact options, full-body MRI* access, and upgradeable technology, the WaveWriter Alpha SCS System equips you and your patients with more choices for tailored pain relief.
Explore product details

Reimbursement

Coding and payment guides

Configure or select a product to continue to order

Every minute counts on the journey to pain relief.

Time matters. Why wait?

Boston Scientific offers the broadest SCS portfolio and an exclusive, automated sub-perception therapy that delivers relief in 2 minutes and lasts for years.

How it works

The WaveWriter Alpha SCS System is the most comprehensive SCS portfolio to allow for full-body MRI* access.‡

Why the WaveWriter Alpha SCS System is right for your practice

The WaveWriter Alpha SCS System is a complete solution tailored to meet you and your patients’ needs at every point in the pain management journey.

An SCS portfolio designed for personalized pain relief:

  • FAST™ Therapy (Fast-Acting Sub-Perception Therapy) is included in all of Boston Scientific’s advanced therapies, and is the only SCS therapy that delivers paresthesia-free pain relief in minutes that lasts for years
  • FAST Therapy allows you to see how your patient is responding before they leave your office
  • Our uniquely designed Infinion™ Pro Percutaneous Lead treats multiple areas of pain with a span of 3 vertebral levels and helps mitigate loss of therapy due to lead migration1
  • The mySCS GO Therapy Controller is a discrete, easy-to-use remote control that makes adjusting SCS therapy settings simple, safe and secure
  • Customizable options that give you flexibility in care with the most comprehensive IPG & lead portfolio in SCS 

Subscribe for updates on the WaveWriter Alpha SCS System

Receive timely access to major announcements, opportunities to connect with your peers through educational events, and useful tools for you to help more patients.

Sign up for updates

Related products

Precision Montage spinal cord stimulator system implantable programmable generator. Precision Montage™ MRI Spinal Cord Stimulator System
Spectra WaveWriter spinal cord stimulator system implantable programmable generator. Spectra WaveWriter™ Spinal Cord Stimulator System

References:

MRI conditional symbol.

The WaveWriter™ Alpha SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha and WaveWriter Alpha Prime Spinal Cord Stimulator System. 

*MRI Conditional under specified conditions 

†Disclaimer: These outcomes reflect approximated data as determined in the referenced studies.

‡ ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha™ and WaveWriter Alpha™ Prime Spinal Cord Stimulator Systems. 92395577-02 

MRI Guidelines for Medtronic Neurostimulation Systems for Chronic Pain. M939858A010 Rev C 

1.5 Tesla and 3 Tesla Magnetic Resonance Imaging (MRI) Guidelines for the SENZA®, SENZA II® & SENZA Omnia™ Systems. 11096 Rev J 

MRI Procedure Information For Abbott Medical MR Conditional Neurostimulation Systems. ARTEN600090483 A 

Sub-perception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia based and sub-perception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.  

FAST MOA computational modeling by Gilbert JE, Titus N, Zhang T, Esteller R, Grill WM. Surround Inhibition Mediates Pain Relief by Low Amplitude Spinal Cord Stimulation: Modeling and Measurement. eNeuro. 2022 Oct 5;9(5):ENEURO.0058-22.2022

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

  1. Tsang et al. Reducing surgical interventions using spinal cord stimulation leads providing long span and tight contact spacing. [Abstract] NANS 2025 Annual Meeting, Jan 30-Feb1, 2025. *compared to a wide-spaced 8-contact lead.

  2. Gage E., et al. Rapid Onset of Analgesia during Trial Period Utilizing Fast-Acting Sub-Perception Therapy SCS [Abstract] NANS 2023 Annual Meeting, Jan 12-15, 2023. (n=44)

  3.  Anitescu M., et al. Utilizing SCS Designed to Engage Surround Inhibition Using Fast-Acting Sub-Perception Therapy (FAST): Prospective, Multicenter, Long-Term Outcomes [Abstract] NANS 2025 Annual Meeting, Jan 30-Feb 1, 2025.   

  4. Metzger C., et al. Two-year Outcomes Using Fast-Acting Sub-perception Therapy for Spinal Cord Stimulation: Results of a Real-World Multicenter Study in the United States. Expert Rev Med Devices. Published online January 2025. (n=50)

  5. Bayerl S., et al. Clinical Outcomes Using A New Fast-Acting Sub-Perception Therapy For Chronic Pain: A Multicenter European Observational Real-World Study [Abstract]. Twenty-Sixth Annual Meeting of the North American Neuromodulation Society, January 12-15, 2023.

  6. Ferro R. et al. Streamlining Spinal Cord Stimulation Therapy via Personalized Automation of Programming [Abstract] NANS 2025 Annual Meeting, Jan 30-Feb 1, 2025. (n=23)

  7. Metzger CS, Hammond MB, Paz-Solis JF, et al. A novel fast-acting sub-perception spinal cord stimulation therapy enables rapid onset of analgesia in patients with chronic pain. Expert Rev Med Devices. 2021 Mar;18(3):299-306. 

  8. Thomson SJ, Tavakkolizadeh M, Love-Jones S, et al. Effects of rate on analgesia in kilohertz frequency spinal cord stimulation; results of the PROCO randomized controlled trial. Neuromodulation. 2018;21(1):67-76. (n=20)

  9. Paz-Solis J. Thomson S, Jain R. Chen L, Huertas I, Doan Q. Exploration of high- and low-frequency options for subperception spinal cord stimulation using neural dosing parameter relationships: the HALO study. Neuromodulation, 2022;25(1):94-102. (n=30) 

  10. North J, Loudermilk E, Lee A, et al. Outcomes of a multicenter, prospective, crossover, randomized controlled trial evaluating subperception spinal cord stimulation at ≤1.2 khz in previously implanted subjects. Neuromodulation. 2020:23(1):102-108. (n=140)

  11. Veizi E, Hayek SM, North J, et al. Spinal cord stimulation (SCS) with anatomically guided (3d) neural targeting shows superior chronic axial low back pain relief compared to traditional scs-lumina study. Pain Med. 2017;18(8):1534-1548. (n=169) 

  12. Wallace MS, North JM, Phillips GM, et al. Combination therapy with simultaneous delivery of spinal cord stimulation modalities: COMBO randomized controlled trial. Pain Manag. 2023:13(3):171-184. (n=59)

  13. Metzger CS, Hammond MB, Pyles ST, et al. Pain relief outcomes using an SCS device capable of delivering combination therapy with advanced waveforms and field shapes, Expert Rev Med Devices. 2020;17(9):951-957. (n=84) 

  14. Metzger C, et al. Long-Term Chronic Pain-Relief Outcomes Using an SCS System Capable of Combination Therapy (WaveWriter Outcomes Study] [Abstract]. Twenty-fifth Annual Meeting of the North American Neuromodulation Society, January 13-15th, 2022. (n=84)

  15. North J., et al. Evaluating SCS and Medical Management for Chronic Pain Without Prior Surgery: SOLIS RCT 24-Month Outcomes [Abstract], NANS 2025 Annual Meeting, Jan 30- Feb l, 2025. (n=77) 

  16. Rauck R. et al. Real-World Outcomes Using Spinal Cord Stimulation for Treatment of Chronic Back Pain with No Prior Back Surgery [Abstract 88). Third joint Congress of the INS European Chapters, August 31-September 2nd, 2023, (n=48)

  17. Berg A et al. Global, Multicenter Registry of Prospectively-Enrolled Patients Utilizing SCS for Painful-Diabetic Peripheral Neuropathy (DPN): Long-Term Outcomes [Abstract]. Twenty-seventh Annual Meeting of the North American Neuromodulation Society, January 18-21, 2024.